公开(公告)号：US11971409B2

公开(公告)日：2024-04-30

申请号：US16892642

申请日：2020-06-04

Applicant: Berkeley Lights, Inc.

Inventor： Kevin T. Chapman ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan Radstrom ,  Jason M. McEwen ,  Gang F. Wang ,  George L. Fox ,  Peggy A. Radel

IPC: B01L3/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543 ,  G01N33/569 ,  G01N33/574

CPC classification number: G01N33/574 ,  B01L3/502761 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/54366 ,  G01N33/56972 ,  B01L2200/0647 ,  G01N2800/7028

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

公开(公告)号：US20170276679A1

公开(公告)日：2017-09-28

申请号：US15406289

申请日：2017-01-13

Applicant: Berkeley Lights, Inc.

Inventor： Kevin T. Chapman ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan ,  Jason M. McEwen ,  Gang Wang ,  George L. Fox ,  Peggy A. Radel

IPC: G01N33/574 ,  C12Q1/68 ,  G01N33/543 ,  B01L3/00

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

公开(公告)号：US20200299351A1

公开(公告)日：2020-09-24

申请号：US16743849

申请日：2020-01-15

Applicant: Berkeley Lights, Inc.

Inventor： Peter J. Beemiller ,  Alexander J. Mastroianni ,  Shao Ning Pei ,  Randall D. Lowe, JR. ,  Annamaria Mocciaro ,  Kevin D. Loutherback ,  Yelena Bronevetsky ,  Guido K. Stadler ,  Andrew W. McFarland ,  Kevin T. Chapman ,  Duane Smith ,  Natalie C. Marks ,  Amanda L. Goodsell

IPC: C07K14/725 ,  C07K16/28 ,  G01N33/50 ,  C07K14/74

Abstract: In biosciences and related fields, it can be useful to modify surfaces of apparatuses, devices, and materials that contact biomaterials such as biomolecules and biological micro-objects. Described herein are surface modifying and surface functionalizing reagents, preparation thereof, and methods for modifying surfaces to activate T Lymphocytes.

公开(公告)号：US20230313107A1

公开(公告)日：2023-10-05

申请号：US18147356

申请日：2022-12-28

Applicant: BERKELEY LIGHTS, INC.

Inventor： Andrew W. McFarland ,  Peter J. Beemiller ,  Guido K. Stadler ,  Alexander J. Mastroianni ,  Joshua J. Cardiel Rivera ,  Darcy K. Kelly-Greene ,  Jonathan Cloud Dragon Hubbard ,  Natalie C. Marks ,  Long Van Le ,  Ke-Chih Lin

IPC: C12M1/00 ,  C12M3/06 ,  C12M3/00 ,  C12M1/34 ,  C12N5/0783

CPC classification number: C12M29/10 ,  C12M23/16 ,  C12M23/40 ,  C12M23/42 ,  C12M41/12 ,  C12M41/36 ,  C12N5/0636 ,  B01L2300/0883

Abstract: Cartridge for manufacturing a population of cells suitable for formulation as a cellular therapeutic are disclosed herein, along with systems for operating the cartridges and performing methods to generate the population of cells suitable for formulation as a cellular therapeutic. The population of cells suitable for formulation as a cellular therapeutic can be T-cells, including CAR T-cells. The systems and methods can be largely automated.

公开(公告)号：US20220325240A1

公开(公告)日：2022-10-13

申请号：US17574459

申请日：2022-01-12

Applicant: Berkeley Lights, Inc.

Inventor： Andrew W. McFarland ,  Peter J. Beemiller ,  Guido K. Stadler ,  Alexander J. Mastroianni ,  Joshua J. Cardiel Rivera ,  Darcy K. Kelly-Greene ,  Jonathan Cloud Dragon Hubbard ,  Natalie C. Marks ,  Long Van Le ,  Ke-Chih Lin

IPC: C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C12M3/00 ,  C12M1/42 ,  C12M1/00

Abstract: Cartridges for manufacturing a population of cells suitable for formulation as a cellular therapeutic are disclosed herein, along with systems and instruments for operating the cartridges and performing methods to generate the population of cells suitable for formulation as a cellular therapeutic. The population of cells suitable for formulation as a cellular therapeutic can be immunological cells, such as T lymphocytes, including endogenous T cells (ETCs), tumor infiltrating lymphocytes (TILs), CAR T-cells, TCR engineered T-cells, or otherwise engineered T-cells. The systems and methods can be largely automated.

公开(公告)号：US20210087252A1

公开(公告)日：2021-03-25

申请号：US16987835

申请日：2020-08-07

Applicant: Berkeley Lights, Inc. ,  The Regents of the University of California

Inventor： Hideho Okada ,  Duane Smith ,  Payal Watchmaker ,  Yelena Bronevetsky ,  Ryosuke Naka ,  Guido K. Stadler ,  Xiaohua Wang ,  Kevin T. Chapman

IPC: C07K14/725 ,  C12N5/0783 ,  C12N15/63

Abstract: This disclosure relates to the production and use of an isolated, purified and/or recombinant T cell receptor (TCR) that specifically binds to a mutant IDH1 protein, or a fragment thereof, wherein the mutant IDH1 protein or fragment thereof comprises an R132H mutation.

公开(公告)号：US10712344B2

公开(公告)日：2020-07-14

申请号：US15406289

申请日：2017-01-13

Applicant: Berkeley Lights, Inc.

Inventor： Kevin T. Chapman ,  George L. Fox ,  Peggy A. Radel ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan Radstrom ,  Jason M. McEwen ,  Gang F. Wang

IPC: B01L3/00 ,  G01N33/574 ,  C07K16/00 ,  G01N33/569 ,  C07K16/28 ,  G01N33/50 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/543

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.